Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR)

Stockholders Encouraged to Contact Securities Law Firm about Investigation

DALLAS—Securities lawyers at Deans & Lyons announce an investigation of the board of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Concerned AEGR investors who purchased between April 30, 2013 and January 9, 2014 are encouraged to contact securities attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.

“Because Aegerion’s stock fell 14.58% after an announcement on January 9, 2014 that the company received a subpoena from the U.S. Department of Justice regarding statements made on CNBC, this potential investigation is concerned with whether operations are affecting stock value for Aegerion Pharmaceuticals, Inc.,” said securities lawyer Hamilton Lindley. “Our potential investigation will seek to ensure that all relevant information is disclosed about the operations of Aegerion Pharmaceuticals, Inc.”

Deans & Lyons has significant experience representing shareholders in securities lawsuits nationwide. AEGR stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at hlindley@deanslyons.com or 877-819-8033 with questions or concerns.

AEGR Intake Form

Bold labels and This graphic indicates a required field. indicate required information.

Enter share information:

Shares Purchased:

Type of Security:
Buy Date:This field is required.
# of Shares:This field is required.
Price per Share:This field is required.

Shares Sold:

Type of Security:
Sell Date:
# of Shares:
Price per Share:

Terms:

Privacy Policy